eprintid: 20811
rev_number: 13
eprint_status: archive
userid: 1589
dir: disk0/00/02/08/11
datestamp: 2016-06-09 09:35:41
lastmod: 2024-03-18 22:13:35
status_changed: 2016-06-09 09:35:41
type: article
metadata_visibility: show
creators_name: Nissen, Johanna C.
creators_name: Hummel, Margit
creators_name: Brade, Joachim
creators_name: Kruth, Jens
creators_name: Hofmann, Wolf-Karsten
creators_name: Buchheidt, Dieter
creators_name: Reinwald, Mark
title: The risk of infections in hematologic patients treated with rituximab is not influenced by cumulative rituximab dosage - a single center experience
subjects: ddc-610
divisions: i-61800
divisions: i-62400
divisions: i-63000
abstract: Background: Rituximab, a monoclonal antibody directed against CD20, is approved for the treatment of CD20-positive B-cell Non-Hodgkin’s lymphoma and rheumatologic disorders. Due to its potent activity in depleting CD20-positive lymphocytes, the influence on opportunistic infections is still under discussion. Thus, we analyzed the impact of rituximab either as monotherapy or in combination with other chemotherapeutic regimens to elucidate its role in contributing to infectious complications.   Methods: The records of consecutive patients (n = 125, 141 treatment episodes) treated with rituximab alone or in combination with chemotherapy and corticosteroids were analyzed retrospectively for the incidence, spectrum and outcome of infections during treatment and 6 months after the last course of rituximab. Univariate analysis of cofactors such as steroid medication, antiinfective prophylaxis, underlying disease and remission status were performed.   Results: Altogether 80 therapy episodes were associated with infections, the median number of infections per patient being 1 (range 1–7). The number of infectious complications was significantly higher in patients receiving a combination of rituximab and chemotherapy compared to rituximab monotherapy (p < 0.001). There was no statistically significant difference regarding number of rituximab courses or cumulative rituximab dosage between episodes with and without infections, respectively.Mean cumulative prednisone dosage between the cohort with infections and the one without infections showed a trend towards higher dosage of prednisone in the patients with infections (mean difference 441 mg, p > 0.14).   Conclusions: Rituximab in induction treatment, either as monotherapy or combined with chemotherapy by itself does not increase the incidence or change the spectrum of infections in hematologic patients. However the possible influence of higher dosages of concomitant steroid medication on frequency of infections suggests that a heightened awareness of the potential for infectious complications should be applied to patients receiving higher doses of glucocorticoids in combination with other therapeutic regimens.
date: 2014
publisher: BioMed Central; Springer
id_scheme: DOI
ppn_swb: 165751112X
own_urn: urn:nbn:de:bsz:16-heidok-208111
language: eng
bibsort: NISSENJOHATHERISKOFI2014
full_text_status: public
publication: BMC Infectious Diseases
volume: 14
number: 364
place_of_pub: London; Berlin; Heidelberg
pagerange: 1-11
issn: 1471-2334
citation:   Nissen, Johanna C. ; Hummel, Margit ; Brade, Joachim ; Kruth, Jens ; Hofmann, Wolf-Karsten ; Buchheidt, Dieter ; Reinwald, Mark  (2014) The risk of infections in hematologic patients treated with rituximab is not influenced by cumulative rituximab dosage - a single center experience.  BMC Infectious Diseases, 14 (364).  pp. 1-11.  ISSN 1471-2334     
document_url: https://archiv.ub.uni-heidelberg.de/volltextserver/20811/1/12879_2013_Article_3699.pdf